greeksoup/ stock research

SBC Medical Group Holdings Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 27 March 2026: press release. The quarter’s numbers.

Key takeaways

  • Fourth-quarter revenue fell 11%: Fourth-quarter total revenues were $39.6 million, down from $44.4 million a year earlier; the release rounds this to $40 million. Full-year revenues were $173.6 million, down 15%. Source
  • Quarterly EPS more than doubled: Fourth-quarter EPS was $0.14, against $0.06 a year earlier. Full-year EPS was $0.50, up 4%. Source
  • Revenue per customer rose 11%: Average revenue per customer was $316 in the fourth quarter, up 11% year over year. Management tied the change to its pricing and customer engagement initiatives. Source
  • EBITDA margin run-rate of 40%: Management said the 40% full-year EBITDA margin, down from 43%, is a more sustainable run-rate going forward. Fourth-quarter EBITDA margin was 34%, down 12 points. Source
  • Structural changes cut revenue: Management attributed the 15% full-year revenue decline mainly to the 2024 restructuring and to franchise fee arrangements revised in April 2025. Source
  • Cash rose to $163.8 million: Cash and equivalents were $163.8 million at year-end, up from $125.0 million. Full-year operating cash flow was $24.7 million, against $20.6 million in 2024. Source
  • Non-aesthetic portfolio added to priorities: Management named three priorities for 2026. The non-aesthetic healthcare item does not appear in the third-quarter release, which listed dermatology and overseas plans. Source

“Our full-year 2025 results reflect a business in transition.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical

What changed from last quarter

  • New: The 2026 priorities add expansion of the non-aesthetic healthcare portfolio, which the third-quarter release did not list. Source
  • New: Equity method investments of $20.3 million were reported at year-end; the prior year-end and the third-quarter balance sheet showed none. Source

Results and growth drivers

  • Fourth-quarter revenue fell 11%: Fourth-quarter total revenues were $39.6 million, down from $44.4 million a year earlier; the release rounds this to $40 million. Full-year revenues were $173.6 million, down 15%. Source
  • Net income attributable rose 117%: Fourth-quarter net income attributable to SBC Medical Group was $14.2 million, against $6.5 million a year earlier. Full-year net income attributable was $51.0 million, up 9%. Source
  • Quarterly EPS more than doubled: Fourth-quarter EPS was $0.14, against $0.06 a year earlier. Full-year EPS was $0.50, up 4%. Source
  • Full-year EBITDA fell 21%: Full-year EBITDA was $70 million, down 21%. Fourth-quarter EBITDA was $14 million, down 35%. Source
  • Other income rose in the quarter: Quarterly total other income was $5.7 million, against $1.3 million, including foreign currency exchange gains of $2.9 million. Source

Revenue sources and clinic network

  • Related-party revenue remained largest share: Related-party revenues were $35.0 million in the fourth quarter, against $42.5 million; other revenues were $4.5 million, against $2.0 million. Full-year related-party revenues were $158.9 million. Source
  • Franchise locations reached 283: Franchise locations were 283 at December 31, 2025, up 34 from a year earlier. The count includes SBC brand, Rize, Gorilla, AHH and JUN CLINIC franchising. Source

“These were deliberate steps to build a more sustainable business foundation, and their financial impact is now largely behind us.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical

Customers and visits

  • Revenue per customer rose 11%: Average revenue per customer was $316 in the fourth quarter, up 11% year over year. Management tied the change to its pricing and customer engagement initiatives. Source
  • Customer count rose 12%: Customers in the last twelve months to December 31, 2025 were 6.6 million, up 12%. Annual customer visits were 6.63 million. Source
  • Repeat rate held at 72%: The repeat rate for customers who visited franchisee clinics twice or more was 72%, unchanged from the third-quarter figure. Source

Costs, margins and pricing

  • SG&A rose 16% in quarter: Fourth-quarter SG&A was $16.1 million, against $13.9 million. The prior-year quarter's stock-based compensation of $0.2 million and impairment loss of $15.1 million did not recur. Source
  • Gross profit fell $4.9 million: Gross profit was $28.9 million, against $33.9 million, while cost of revenues was $10.6 million, against $10.5 million. Source
  • Net income margin rose to 29%: Full-year net income margin was 29%, against 23% in 2024. Fourth-quarter net income margin was 36%, against 15%. Source
  • Tax expense rose on higher profit: Fourth-quarter income tax expense was $4.3 million, against a benefit of $0.5 million. Full-year tax expense was $31.0 million, against $26.8 million. Source
  • EBITDA margin run-rate of 40%: Management said the 40% full-year EBITDA margin, down from 43%, is a more sustainable run-rate going forward. Fourth-quarter EBITDA margin was 34%, down 12 points. Source

“In the fourth quarter specifically, we saw encouraging operational momentum.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical

Restructuring and fee revision

  • Structural changes cut revenue: Management attributed the 15% full-year revenue decline mainly to the 2024 restructuring and to franchise fee arrangements revised in April 2025. Source
  • Q3 cited the same two causes: The third-quarter release gave the same main causes for its 18% revenue decline, including the deconsolidation of certain group entities.
  • Staff support services discontinued: The third-quarter release also cited lower management services revenue after the discontinuation of clinic operation staff support.

Capital, cash and returns

  • Cash rose to $163.8 million: Cash and equivalents were $163.8 million at year-end, up from $125.0 million. Full-year operating cash flow was $24.7 million, against $20.6 million in 2024. Source
  • Acquisitions and equity stake purchases: Cash paid for acquisitions of subsidiaries, net of cash acquired, was $22.9 million, and purchases of equity method investments were $20.1 million. Source
  • Treasury stock rose to $7.7 million: Treasury stock was 1,304,308 shares at cost of $7.7 million, up from $2.7 million; the cash flow statement shows $5.0 million of common stock repurchases. Source
  • Return on equity reached 23%: Return on equity was 23%, a 9.8-point increase year over year, measured as net income attributable divided by average shareholder equity. Source

Strategy and investment priorities

  • Non-aesthetic portfolio added to priorities: Management named three priorities for 2026. The non-aesthetic healthcare item does not appear in the third-quarter release, which listed dermatology and overseas plans. Source
  • Equity stake and goodwill increased: Year-end equity method investments were $20.3 million, with none at the prior year-end; goodwill rose to $15.4 million from $4.6 million. Source
  • Overseas expansion through medical tourism: The company describes itself as expanding its global presence, particularly in the United States and Asia, through direct operations and medical tourism. Source

Figures management reported

FigureReported
Customers, last twelve months Source6.6 million (up 12%)
Annual customer visits Source6.63 million
Repeat rate, customers visiting twice or more Source72%
Average revenue per customer Source$316 (up 11%)
Franchise locations Source283 (up 34)

Earlier plans management reported on

  • Not stated: The third-quarter release said the company would pursue sustainable growth toward 2026 through three focus areas. The fourth-quarter release restates these as 2026 priorities.
  • Not stated: The third-quarter release said the cost base was normalizing. The fourth-quarter release says IPO-related stock-based compensation and impairment losses did not recur.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.